1. Switzerland Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Lonza Group AG

Lonza Group AG

677.20
EUR
+7.20
(+1.07%)
41.31BMarket Cap
Jan 27Next Earn
Lonza Group AG
DUS:LO3
(Dusseldorf Stock Exchange)

Recent

price

677.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CHF
47.37
48.29
70.22
63.91
64.86
67.4
72.85
67
74.48
56.77
60.59
72.84
83.83
91.23
76.99
93.27
- -
Revenue per Share
5.02
2.76
3.11
1.55
4.22
4.91
5.31
10.42
7.51
8.7
11.68
39.65
16.37
8.88
8.94
-3.93
- -
Basic EPS, GAAP
2.74
-0.83
7.16
5.55
5.4
8.45
6.81
5.75
6.81
2.42
2.11
-1.67
-11.48
-3.99
-2.01
-3.1
- -
Free Cash Flow per Basic Share
1.63
1.99
1.99
2
2
2.32
2.31
2.36
2.77
2.78
2.77
3.03
3.07
3.57
4.05
4.03
- -
Dividend per Share
42.13
38.37
37.48
37.89
37.93
37.83
40.39
82.61
83.75
87.42
91.74
131.42
142.66
131.07
132.06
113.29
116.26
Book Value per Share
30.59
2.3
3.1
4.94
2.19
3.26
0.82
-21.15
-11.34
-3.1
14.85
58.09
74.08
65.34
56.02
80.54
83.63
Tangible Book Value per Share
57
56
56
56
56
56
57
68
74
74
74
74
74
74
71
70
70
Basic Weighted Avg Shares
2,680
2,692
3,925
3,584
3,640
3,803
4,132
4,548
5,542
4,207
4,508
5,409
6,223
6,717
5,480
6,531
- -
Sales/Revenue/Turnover
13.96
9.7
8.66
7.06
11.62
11.39
12.92
14.31
16.37
20.2
20.67
15.29
21.81
13
16.04
20.79
- -
Operating Margin (%)
273
276
304
309
299
300
307
411
526
544
526
522
596
621
647
813
- -
Depreciation Expense
284
154
174
87
237
277
301
707
559
645
869
2,944
1,215
654
636
-275
- -
Net Income, GAAP
13.94
12
17.14
17.14
15.05
18.77
19.3
- -
18.34
9.87
8.84
10.92
15.88
17.09
14.97
17.44
- -
Effective Tax Rate (%)
10.6
5.72
4.43
2.43
6.51
7.28
7.28
15.55
10.09
15.33
19.28
54.43
19.52
9.74
11.61
-4.21
- -
Profit Margin (%)
336
866
661
655
323
268
433
560
1,134
365
1,704
3,585
2,637
2,139
1,861
3,209
2,764
Working Capital
910
2,725
2,427
2,245
1,693
1,414
1,571
3,730
3,621
2,985
2,994
2,530
1,855
2,905
4,608
4,197
3,393
LT Debt
2,387
2,137
2,102
2,126
2,130
2,135
2,302
6,181
6,290
6,565
6,884
9,823
10,665
9,512
9,388
7,966
8,152
Total Equity
8.24
5.09
11.09
4.32
7.89
8.11
9.34
- -
6.44
7.08
7.69
6.44
9.96
5.6
5.65
7.53
- -
Return on Invested Capital (%)
8.26
4.44
5.46
3.71
6.73
8.12
8.78
- -
6.11
6.87
8.85
25.87
9.8
5.64
5.55
-1.04
- -
Return on Capital (%)
12.05
6.81
8.21
4.11
11.14
12.99
13.57
16.76
9.05
10.15
13.06
35.54
11.94
6.52
6.77
-3.19
- -
Return on Common Equity (%)

Capital Structure

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
415
343
774
LT Borrowings
4,199
3,876
3,393
LT Finance Leases
- -
321
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
70
70
70
Market Capitalization
39,434
37,472
38,122

Working Capital

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
4,589
6,834
6,936
Cash, Cash Equivalents & STI
907
719
487
Accounts Receivable, Net
1,805
1,062
1,920
Inventories
1,843
1,680
1,880
Total Current Liabilities
3,151
3,625
4,172
Payables & Accruals
- -
- -
- -
ST Debt
415
343
774
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.13%
4.8%
-15.15%
Free Cash Flow
27.8%
68.6%
51.75%
Net Income, GAAP
16.06%
-2.42%
-143.24%
Sales/Revenue/Turnover
6.74%
8.75%
19.18%
Total Cash Common Dividend
- -
6.67%
-2.08%

Semi-annual Revenue

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
5,480
2025
- -
- -
6,531
2026
- -
- -
- -

Semi-annual Earnings Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
8.94
2025
- -
- -
-3.93
2026
- -
- -
- -

Semi-annual Dividends Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
4.05
2025
- -
- -
4.03
2026
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Lonza Group AG is a leading contract development and manufacturing organization (CDMO) in the biopharmaceutical industry, providing end-to-end solutions for biologics, small molecules, cell and gene therapies, and microbial products. The company offers services including cell line development, process development, analytical services, clinical and commercial manufacturing, and formulation technologies such as encapsulated cell therapies and lipid nanoparticles; its key product categories encompass monoclonal antibodies, bispecifics, mRNA vaccines, viral vectors, and biosimilars, supported by proprietary platforms like Cocoon for personalized medicines and Lysogenix for biocatalysis. Lonza operates globally across North America, Europe, Asia-Pacific, and Latin America, serving pharmaceutical, biotech, and academic customers with facilities in Switzerland, the United States, Singapore, and China. Founded in 1897 and headquartered in Basel, Switzerland (ticker: LONN.SW), Lonza focuses on accelerating drug development and commercialization through its expertise in bioconjugates, antibody-drug conjugates, and advanced therapy medicinal products. In the past two years, Lonza has expanded through strategic moves including the 2024 acquisition of In Vitro Technologies to bolster Australian operations, a multi-year partnership with NVIDIA in 2025 to integrate AI into bioprocessing for faster drug discovery, the launch of a new bioconjugates facility in Boston in 2024, and a CHF 1 billion investment announced in 2025 for cell and gene therapy capacity in the US and Europe to meet surging demand in personalized medicines.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Lonza: Strong H1 Execution, Higher Guidance Means Higher Upside

  • seekingalpha.com

    Lonza Group AG (LZAGY) Q1 2026 Earnings Call Transcript